SinoMab BioScience Limited (HKG:3681)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.180
-0.020 (-1.67%)
Jun 18, 2026, 11:58 AM HKT
Market Cap1.66B +26.0%
Revenue (ttm)n/a
Net Income-116.83M
EPS-0.10
Shares Out 1.39B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume666,600
Open1.210
Previous Close1.200
Day's Range1.180 - 1.220
52-Week Range1.010 - 3.760
Beta0.64
AnalystsStrong Buy
Price Target3.13 (+165.25%)
Earnings DateAug 19, 2026

About SinoMab BioScience

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-class anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 95
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3681
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements